Analysts have warned that the extraordinary growth outlook for drugs such as Novo Nordisk’s Wegovy and Ozempic, which is prescribed for diabetes but commonly used for weight loss, could hit sales of packaged food and drinks as patients reduce their calorie intake.
Read the full article on the Financial Times website (PayWall)
